BCRX Biocryst Pharmaceuticals Inc

Price (delayed)

$8.785

Market cap

$2.23B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.73

Enterprise value

$2.92B

?
Relative Growth: Rel. Growth: 30
Relative Strength: Rel. Strength: 62
Relative Valuation: Rel. Valuation: 18
Relative Profitability: Rel. Profitability: 18

BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema and other rare diseases. BioCryst leverages its expertise in ...

Highlights
Biocryst Pharmaceuticals's gross profit has soared by 77% YoY
BCRX's revenue has soared by 76% YoY
BCRX's debt has soared by 80% QoQ and by 3.5% YoY
Biocryst Pharmaceuticals's quick ratio has decreased by 36% YoY and by 9% QoQ

Key stats

What are the main financial stats of BCRX

BCRX stock price

How has the Biocryst Pharmaceuticals stock price performed over time
Intraday
-2.17%
1 week
-8.3%
1 month
-10.72%
1 year
10.5%
YTD
12.63%
QTD
-12.15%

Financial performance

How have Biocryst Pharmaceuticals's revenue and profit performed over time
Revenue
$885.72M
Gross profit
$865.83M
Operating income
-$381.84M
Net income
-$457.98M
Gross margin
97.8%
Net margin
-51.7%
Biocryst Pharmaceuticals's gross profit has soared by 77% YoY
BCRX's revenue has soared by 76% YoY

Price vs fundamentals

How does BCRX's price correlate with its fundamentals

Growth

What is Biocryst Pharmaceuticals's growth rate over time

Valuation

What is Biocryst Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
2.4
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.3
BCRX's equity is down by 23% year-on-year
BCRX's revenue has soared by 76% YoY
The P/S is 63% lower than the 5-year quarterly average of 6.6 and 5% lower than the last 4 quarters average of 2.6

Efficiency

How efficient is Biocryst Pharmaceuticals business performance

Dividends

What is BCRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BCRX.

Financial health

How did Biocryst Pharmaceuticals financials performed over time
Biocryst Pharmaceuticals's total assets is 54% lower than its total liabilities
The total liabilities has soared by 61% from the previous quarter and by 9% YoY
Biocryst Pharmaceuticals's quick ratio has decreased by 36% YoY and by 9% QoQ
BCRX's debt has soared by 80% QoQ and by 3.5% YoY
BCRX's debt to equity has surged by 61% since the previous quarter and by 16% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.